Table 2.
Autoantibody data during therapy
| Autoantibody positivity at IP1, n = 63 n (% of n = 63) | Autoantibody negativity at IP1, n = 107 n (% of n = 107) | All patients, n = 170 n (% of n = 170) | |
|---|---|---|---|
| New occurrence of autoantibodies during therapya | 34 (54) | 64 (60) | 98 (58) |
| New occurrence before IP2/3 | 14 (22) | 38 (36) | 52 (31) |
| PCA | 4 (6) | 5 (5) | 9 (5) |
| ANA | 3 (5) | 10 (9) | 13 (8) |
| SMA | 2 (3) | 21 (20) | 23 (14) |
| ACyA | 2 (3) | 3 (3) | 5 (3) |
| xANCA | 1 (2) | 4 (4) | 5 (3) |
| Anti-TG/anti-TPO | 1 (2) | 6 (6) | 7 (4) |
| pANCA | 1 (2) | 1 (1) | 2 (1) |
| AMiA | 1 (2) | 0 (0) | 1 (1) |
| AMA | 0 (0) | 1 (1) | 1 (1) |
| Anti-LKM | 0 (0) | 1 (1) | 1 (1) |
| New occurrence before MT | 8 (13) | 11 (10) | 19 (11) |
| PCA | 7 (11) | 3 (3) | 10 (6) |
| ANA | 1 (2) | 5 (5) | 6 (4) |
| SMA | 1 (2) | 3 (3) | 4 (2) |
| Anti-TG/anti-TPO | 1 (2) | 0 (0) | 1 (1) |
| pANCA | 0 (0) | 1 (1) | 1 (1) |
| ACyA | 0 (0) | 0 (0) | 0 (0) |
| xANCA | 0 (0) | 0 (0) | 0 (0) |
| AMiA | 0 (0) | 0 (0) | 0 (0) |
| AMA | 0 (0) | 0 (0) | 0 (0) |
| Anti-LKM | 0 (0) | 0 (0) | 0 (0) |
| New occurrence before BP1 | 8 (13) | 15 (14) | 23 (14) |
| SMA | 3 (5) | 10 (9) | 13 (8) |
| PCA | 4 (6) | 5 (5) | 9 (5) |
| Anti-TG/anti-TPO | 2 (3) | 0 (0) | 2 (1) |
| xANCA | 1 (2) | 0 (0) | 1 (1) |
| ACyA | 0 (0) | 0 (0) | 0 (0) |
| Anti-LKM | 0 (0) | 0 (0) | 0 (0) |
| ANA | 0 (0) | 1 (1) | 1 (1) |
| pANCA | 0 (0) | 0 (0) | 0 (0) |
| AMiA | 0 (0) | 0 (0) | 0 (0) |
| AMA | 0 (0) | 0 (0) | 0 (0) |
| New occurrence before BP2-4 | 14 (22) | 21 (20) | 35 (21) |
| SMA | 8 (13) | 12 (11) | 20 (12) |
| PCA | 5 (8) | 12 (11) | 17 (10) |
| Anti-TG/anti-TPO | 0 (0) | 2 (2) | 2 (1) |
| xANCA | 0 (0) | 0 (0) | 0 (0) |
| ACyA | 1 (2) | 1 (1) | 2 (1) |
| Anti-LKM | 1 (2) | 0 (0) | 1 (1) |
| ANA | 0 (0) | 1 (1) | 1 (1) |
| pANCA | 0 (0) | 0 (0) | 0 (0) |
| AMiA | 0 (0) | 0 (0) | 0 (0) |
| AMA | 0 (0) | 0 (0) | 0 (0) |
ACyA, anti-cytoplasmatic antibodies; AMA, anti-mitochondrial antibodies; AMiA, anti-mitotic antibodies; ANA, anti-nuclear antibodies; BP1-4, time points 1-4 during boost phase; IP1-3, time points 1-3 during induction phase; LKM, liver kidney microsome; MT, time point during maintenance therapy; pANCA, perinuclear anti-neutrophil cytoplasmatic antibodies; PCA, parietal cell antibodies; SMA, smooth muscle antibodies; TG, thyroglobulin; TPO, thyroid peroxidase; xANCA, atypical anti-neutrophil cytoplasmatic antibodies.
a
Patients could experience a new occurrence of autoantibodies during multiple study phases.